Published in

Oxford University Press, The Journal of Infectious Diseases, 5(203), p. 610-619, 2011

DOI: 10.1093/infdis/jiq105

Links

Tools

Export citation

Search in Google Scholar

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

Journal article published in 2011 by Paul A. Goepfert, Alicia Sato, Li Qin, Georgia D. Tomaras, David C. Montefiori, Yongxian Xu, Linda S. Wyatt, Bernard Moss, Marnie L. Elizaga, Harriet L. Robinson, Massimo Cardinali, Christine M. Hay, John Hural, Stephen C. DeRosa, Olivier D. DeFawe and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background. Recombinant DNA and modified vaccinia virus Ankara (rMVA) vaccines represent a promising approach to an HIV/AIDS vaccine. This Phase 1 clinical trial compared the safety and immunogenicity of a rMVA vaccine administered with and without DNA vaccine priming